Physician profile
Michael Mayhall
NPI 1689049660
$763.32
in general payments reported to CMS, 2019-2025
10 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.72 · 2022: $125 · 2024: $126 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $187.77 | 2021-2025 | Wegovy |
| Axsome Therapeutics, INC. | $142.43 | 2025 | Auvelity |
| Horizon Therapeutics Plc | $124.97 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.51 | 2024-2025 | Caplyta |
| Abbvie INC. | $59.00 | 2024-2025 | |
| Abbott Laboratories | $45.10 | 2024-2025 | Supera |
| Phathom Pharmaceuticals, INC. | $35.07 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $21.52 | 2025 | Gemtesa |
| Vanda Pharmaceuticals INC. | $19.73 | 2024 | Fanapt, Hetlioz |
| Astrazeneca Pharmaceuticals LP | $18.22 | 2025 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mayhall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.